Gilead Sciences acquires Arcellx

Gilead Sciences agreed to acquire Arcellx. Reported deal value: $7.8B. Status: Announced. Sector: biotechnology. Target headquarters context: Redwood City, California, United States.

This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.

WhatsApp Anito - cel moves closer to potential approval as Maryland-founded biotech becomes cornerstone asset in cel l therapy expansion In a defining move for the cel l therapy sector, Gilead Sciences has entered into a definitive agreement to acquire Ar cel lx for an implied equity value of $7.8 billion